Cancer treatment paradigms

Telegraphic trial summaries · NCCN / ESMO / ASCO / ICMR context · a “What it means for India” note in every post.

Subtopics

• First-line systemic therapy · Lung · Breast · GI · Bladder / GU · Sarcoma · Immunotherapy — dostarlimab · Trial briefs · FDA approvals · Conferences

First-line systemic therapy

• First-line systemic therapy in advanced cancers

Lung

• FLAURA2 — osimertinib + chemotherapy

Breast

• DESTINY-Breast11

GI

• ASCO GI 2026 — HERIZON-GEA-01, BREAKWATER, COMMIT

Bladder / GU

• Advanced bladder (urothelial) cancer

Sarcoma

• DeFi — nirogacestat in desmoid tumours

Immunotherapy — dostarlimab

• Dostarlimab in MSI-H/dMMR rectal cancer
• New 5 Nov 2026: organ-preservation pathway illustration

Trial briefs

• Trial briefs, October 2026

FDA approvals

• New 8 Nov 2026: Rybrevant Faspro (amivantamab) for pretreated HNSCC
• FDA oncology approvals, October 2026
• Three oncology FDA decisions to watch in November 2026

Conferences

• ESMO 2026 Madrid hub · ESMO 2026 week update (2–6 Nov) · ESMO 2026 trial matching game · Best of cancer media